Opthea Limited
http://www.opthea.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Opthea Limited
Finance Watch: Have Investors Reached IPO Fatigue?
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Pipeline Watch: Phase III Progress With Semaglutide, Sotagliflozin
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Chugai deal positions Circadian as "dominant" player in VEGF-D rights
Roche's Japanese subsidiary, Chugai, has granted the Australian bioventure Circadian exclusive worldwide rights to its intellectual property (IP) estate in the area of vascular endothelial growth factor D (VEGF-D).
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Ceres Oncology Pty Ltd
- Circadian Technologies Limited
- Opthea Pty Ltd
- Vegenics Pty Limited